

EXHIBIT 1067

'435 Application Pending Claim (January 28, 2022) (Ex-1015, 179)	'757 Patent Claim 1 (Ex-1001, Cl. 1)
A pharmaceutical composition comprising <i>at least 2 immunogenic saccharide polypeptide conjugates each comprising individually a capsular polysaccharide</i>, fragment thereof, or combination thereof, <i>conjugated to a polypeptide</i>, wherein the capsular polysaccharide, fragment thereof, or combination thereof is from a <i>unique Streptococcus pneumoniae serotype</i> group, wherein a first serotype is selected from the group consisting of 6C, 15A, 16F, 20B, 24F, 31, and 34 and at least one additional <i>serotype is selected from the group consisting of</i> 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 20A, 22F, 23A, 23B, 24F, 31, 33F, 34, 35B, and 38, wherein the at least one additional serotype is not the first serotype.	A pharmaceutical composition comprising a plurality of <i>at least two</i> unique <i>immunogenic saccharide-polypeptide conjugates</i>, each comprising individually a capsular polysaccharides conjugated to a polypeptide, wherein each of the capsular polysaccharides is from a Streptococcus pneumoniae serotype selected from a group consisting of 23A, 23B, and 35B.

'435 Application Pending Claim - September 27, 2025 Amendment (Ex-1015, 1487–88):

A pharmaceutical composition comprising

a plurality of at least two^{[[2]]} immunogenic saccharide-polypeptide conjugates, each **comprising individually** a capsular polysaccharide, fragment thereof, or combination thereof, conjugated to a polypeptide,

wherein the capsular polysaccharide, fragment thereof, or combination thereof is from a unique *Streptococcus pneumoniae* ~~*Streptococcus pneumoniae*~~ serotype group,

wherein a first serotype comprises ~~is selected from the group consisting of 6C, 15A, 16F, 20A, 20B, 24F, or 31, and 34~~ and at least one

additional serotype comprises ~~is selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19A, 19F, 20A, 20B, 22F, 23A, 23B, 23F, 24F, 31, 33F, 34, 35B, or [[and]] 38,~~

wherein the at least one additional serotype is not the first serotype; and
wherein the fragment of the capsular polysaccharide is a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, a pentasaccharide, a hexasaccharide, or an oligosaccharide.

'435 Application Pending Claim - October 2, 2025 Amendment (Ex-1015, 1937–42):

A pharmaceutical composition comprising

a plurality of at least two immunogenic saccharide-polypeptide conjugates, each immunogenic saccharide-polypeptide conjugate comprising individually consisting of a capsular polysaccharide, fragment thereof, or combination thereof, conjugated to a polypeptide,

wherein the capsular polysaccharide, fragment thereof, or combination thereof is from a unique *Streptococcus pneumoniae* serotype,

wherein a first serotype comprises 16F, 20A, 20B, 24F, or 31, and at least one additional serotype comprises 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19A, 19F, 20A, 20B, 22F, 23A, 23B, 23F, 24F, 31, 33F, 34, 35B, or 38,

wherein the at least one additional serotype is not the first serotype; and

wherein the fragment of the capsular polysaccharide is a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, a pentasaccharide, hexasaccharide, or an oligosaccharide.